MedTrace Logo

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

NCT02718430 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-10-19

No results posted yet for this study

Summary

Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01

Conditions

Interventions

DRUG

VXM01

Oral immunotherapy targeting VEGFR2

Sponsors & Collaborators

  • Vaximm GmbH

    lead INDUSTRY

Principal Investigators

  • Carsten Gruellich, MD · National Center of Tumor Diseases Heidelberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02718430 on ClinicalTrials.gov